[go: up one dir, main page]

ATE346615T1 - Mittel zur verbesserung der gewebepenetration - Google Patents

Mittel zur verbesserung der gewebepenetration

Info

Publication number
ATE346615T1
ATE346615T1 AT02742998T AT02742998T ATE346615T1 AT E346615 T1 ATE346615 T1 AT E346615T1 AT 02742998 T AT02742998 T AT 02742998T AT 02742998 T AT02742998 T AT 02742998T AT E346615 T1 ATE346615 T1 AT E346615T1
Authority
AT
Austria
Prior art keywords
agents
tissue penetration
improving tissue
diluents
active agent
Prior art date
Application number
AT02742998T
Other languages
English (en)
Inventor
Hansjoerg Eibl
Peter Hoffmann
Original Assignee
Max Planck Gesellschaft
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Genzyme Corp filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE346615T1 publication Critical patent/ATE346615T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/03Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04Saturated ethers
    • C07C43/13Saturated ethers containing hydroxy or O-metal groups
    • C07C43/135Saturated ethers containing hydroxy or O-metal groups having more than one ether bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT02742998T 2001-05-11 2002-05-13 Mittel zur verbesserung der gewebepenetration ATE346615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10122855A DE10122855A1 (de) 2001-05-11 2001-05-11 Mittel zur Verbesserung der Gewebepenetration

Publications (1)

Publication Number Publication Date
ATE346615T1 true ATE346615T1 (de) 2006-12-15

Family

ID=7684371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02742998T ATE346615T1 (de) 2001-05-11 2002-05-13 Mittel zur verbesserung der gewebepenetration

Country Status (11)

Country Link
US (5) US20040146535A1 (de)
EP (1) EP1387699B1 (de)
JP (1) JP5433866B2 (de)
KR (1) KR100604435B1 (de)
AT (1) ATE346615T1 (de)
AU (1) AU2002342304B2 (de)
CA (1) CA2446659C (de)
DE (2) DE10122855A1 (de)
IL (1) IL158698A0 (de)
NZ (1) NZ529142A (de)
WO (1) WO2002092130A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098713A (en) * 1975-12-24 1978-07-04 The Procter & Gamble Company Detergent compositions
JPS6028946A (ja) * 1983-07-28 1985-02-14 Kao Corp テルペンアルコ−ルのジグリセリンアルキルエ−テル及びこれを含有する化粧料
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
JP2513614B2 (ja) * 1983-12-01 1996-07-03 マツクス−プランク−ゲゼルシヤフト ツ−ル フエルデルング デルヴイツセンシヤフテン エ− フアウ 組織薄膜の透過率を改善した薬物
JPS61205277A (ja) * 1985-03-08 1986-09-11 Pola Chem Ind Inc 新規エポキシ化合物
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DK0880530T3 (da) * 1996-02-16 2003-10-27 Max Planck Gesellschaft Phosphatidyloligoglyceroler
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
JP2000143441A (ja) * 1998-11-10 2000-05-23 Kao Corp メイクアップ除去剤
DE19959000B4 (de) * 1999-12-08 2018-07-05 Cognis Ip Management Gmbh Verwendung primärer Monoalkylether von Eigenkondensationsprodukten des Glycerins
KR100393478B1 (ko) * 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제

Also Published As

Publication number Publication date
CA2446659C (en) 2011-08-16
AU2002342304B2 (en) 2007-11-29
CA2446659A1 (en) 2002-11-21
IL158698A0 (en) 2004-05-12
EP1387699A1 (de) 2004-02-11
US20160031781A1 (en) 2016-02-04
DE60216441T2 (de) 2007-03-15
US20090312440A1 (en) 2009-12-17
JP2004530688A (ja) 2004-10-07
US20120064147A1 (en) 2012-03-15
EP1387699B1 (de) 2006-11-29
KR20030097858A (ko) 2003-12-31
WO2002092130A1 (en) 2002-11-21
US20040146535A1 (en) 2004-07-29
DE10122855A1 (de) 2002-11-14
KR100604435B1 (ko) 2006-07-25
NZ529142A (en) 2004-09-24
JP5433866B2 (ja) 2014-03-05
US20080003277A1 (en) 2008-01-03
DE60216441D1 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
BR0317715A (pt) Composições e processos de uso de collajolie
ATE297203T1 (de) Antithrombotische mitteln
EA200200208A1 (ru) Синергитическая композиция
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
ATE306261T1 (de) Antithrombosemittel
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
PE20031012A1 (es) Compuesto inhibidor de la hepatitis c
EE04912B1 (et) N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
DE60121461D1 (de) Kondensierte pyridoindolderivate
DE60120881D1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
BR0012696A (pt) Composição oftálmica
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
DE60128100D1 (de) Analgetisches arzneimittel
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
ATE308540T1 (de) Antithrombosemittel
SE0004101D0 (sv) New use
ATE187461T1 (de) Cyklopeptolide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties